{{Rsnum
|rsid=2242592
|Gene=DRD2
|Chromosome=11
|position=113408708
|Orientation=minus
|GMAF=0.489
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 8.8 | 49.6 | 41.6
| HCB | 31.6 | 46.3 | 22.1
| JPT | 27.7 | 48.2 | 24.1
| YRI | 66.2 | 27.6 | 6.2
| ASW | 33.3 | 50.9 | 15.8
| CHB | 31.6 | 46.3 | 22.1
| CHD | 26.9 | 55.6 | 17.6
| GIH | 15.8 | 52.5 | 31.7
| LWK | 62.4 | 36.7 | 0.9
| MEX | 8.6 | 37.9 | 53.4
| MKK | 63.9 | 32.3 | 3.9
| TSI | 5.9 | 39.2 | 54.9
| HapMapRevision=28
}}{{PMID Auto
|PMID=19772578
|Title=Two-stage case-control association study of dopamine-related genes and migraine
|OA=1
}}

{{PMID|19197363|OA=1
}} A genome-wide investigation of SNPs and CNVs in schizophrenia.

{{PMID|19968402|OA=1
}} Evaluation of genetic variability in the dopamine receptor D2 in relation to behavioral inhibition and impulsivity/sensation seeking: an exploratory study with d-amphetamine in healthy participants.

{{PMID|20138949}} A genetic schizophrenia-susceptibility region located between the ANKK1 and DRD2 genes.

{{PMID Auto
|PMID=22893251
|Title=Influence of ANKK1 and DRD2 polymorphisms in response to haloperidol.
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}